5% Cmax-rule only in SD [Study As­sess­ment]

posted by Helmut Homepage – Vienna, Austria, 2019-03-31 14:52 (850 d 07:19 ago) – Posting: # 20107
Views: 2,858

Hi Hiren,

please see this post (#3 and #5). Without knowing the regulation you are bound to and more details about the study we are fishing in the dark.

» We did a multiple dose (5 weeks, 1 TDS patch every week) bioequivalence study. The BE was assessed at week 5 at steady state. It was a 3-period study. In period 2 and 3, we observed some carry-over from the previous period treatments. I remember, the 5% of Cmax rule for single-dose studies.

Correct (EMA, FDA). Equal carry-over does not bias the estimated treatment effect, whereas unequal carry-over will (to an unknown degree). Since no statistical method exists to correct the later, it has to be avoided by design (in SD sufficiently long washout or – in the case of steady state / switch-over – washout from one treatment overlapping built-up of steady state of the other).

» But, can someone please throw some light on how to handle this carry-over in multiple dose steady state studies?

Since you mentioned steady state, I assume relevant accumulation (otherwise, f.i. according to the EMA’s GL the multiple dose study can be waived). By definition (superposition principle of linear PK) you will observe residual concentrations from earlier doses. Hence, the exclusion-rule does not make any sense. I hope you didn’t state it in the protocol.

» Does the carry-over in week 1 pre-dose really impact week 5 steady state parameters?

Don’t understand what you mean.

@Nirali: Why should that matter?

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,590 posts in 4,513 threads, 1,531 registered users;
online 4 (0 registered, 4 guests [including 4 identified bots]).
Forum time: Wednesday 22:11 CEST (Europe/Vienna)

If a man will begin with certainties, he will end in doubts;
but if he will be content to begin with doubts,
he will end in certainties.    Francis Bacon

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz